智通财经APP获悉，微创脑科学(02172)盘中涨超10%，截至发稿，涨4.74%，报9.72港元，成交额5258.95万港元。
消息面上，微创脑科学发布盈喜，预计2024年度净利润2.36亿至2.7亿人民币，同比增长约75%至100%。主要因为产品入院覆盖及市场份额提升，且海外业务收入实现翻倍增长；公司通过执行供应链改善及成本节约措施，运营效率提升。广发证券指出，市场推广及运营效率持续提升，公司24年预期盈利水平稳健增长；公司核心产品加速入院，新产品丰富产品线。
智通财经APP在《微创脑科学（02172）:集采最大受益方？》中指出，对于大多数医药行业来说，集采基本上是利空。但神经介入国产企业市场占有率低，集采的推动加速国产化，反而形成利好。对于国产神经介入器械企业而言，短期内，仍看集采政策力度，集采加速推进，对这些企业形成利好，业绩有望高增；中长期而言，当国内集采后，市场竞争格局处于相对稳定，企业业绩能否进一步高速增长，出海是关键。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.